• Explore /
  • Poster
  • / Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.

Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.

Abstract Poster

Authors

null

Haruko Daga

Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan

Haruko Daga , Koji Takeda , Hideaki Okada , Masaki Miyazaki , Shinya Ueda , Hiroyasu Kaneda , Isamu Okamoto , Kiyotaka Yoh , Koichi Goto , Koichi Konishi , Akiko Sarashina , Nobutaka Yagi , Kiyomi Mera , Rolf Kaiser , Kazuhiko Nakagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT00979576

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8056)

DOI

10.1200/jco.2013.31.15_suppl.8056

Abstract #

8056

Poster Bd #

34D

Abstract Disclosures

Similar Posters

First Author: Tomoya Yokota

First Author: Filippo G. De Braud

First Author: Quincy S. Chu

First Author: Helena Alexandra Yu